WO2016205784A1 - Methods and compositions for producing activated natural killer cells and related uses - Google Patents
Methods and compositions for producing activated natural killer cells and related uses Download PDFInfo
- Publication number
- WO2016205784A1 WO2016205784A1 PCT/US2016/038338 US2016038338W WO2016205784A1 WO 2016205784 A1 WO2016205784 A1 WO 2016205784A1 US 2016038338 W US2016038338 W US 2016038338W WO 2016205784 A1 WO2016205784 A1 WO 2016205784A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- seq
- nos
- antibody
- aml
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 155
- 238000000034 method Methods 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 360
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 191
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract description 183
- 239000000556 agonist Substances 0.000 claims abstract description 95
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 238000012258 culturing Methods 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims abstract description 9
- 101100261153 Mus musculus Mpl gene Proteins 0.000 claims abstract 16
- 230000027455 binding Effects 0.000 claims description 53
- 208000032839 leukemia Diseases 0.000 claims description 37
- 239000000427 antigen Substances 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 210000001185 bone marrow Anatomy 0.000 claims description 30
- 102000001398 Granzyme Human genes 0.000 claims description 22
- 108060005986 Granzyme Proteins 0.000 claims description 22
- 102000004503 Perforin Human genes 0.000 claims description 21
- 108010056995 Perforin Proteins 0.000 claims description 21
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims description 21
- 229930192851 perforin Natural products 0.000 claims description 21
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 19
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 108010074328 Interferon-gamma Proteins 0.000 claims description 14
- 102000008070 Interferon-gamma Human genes 0.000 claims description 14
- 229960003130 interferon gamma Drugs 0.000 claims description 14
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 230000001154 acute effect Effects 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 11
- 230000035800 maturation Effects 0.000 claims description 11
- 210000001167 myeloblast Anatomy 0.000 claims description 11
- 210000005259 peripheral blood Anatomy 0.000 claims description 10
- 239000011886 peripheral blood Substances 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 9
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 8
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 239000002771 cell marker Substances 0.000 claims description 7
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims description 6
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims description 6
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims description 6
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims description 4
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 claims description 4
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 206010014950 Eosinophilia Diseases 0.000 claims description 3
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 3
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims description 3
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 3
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims description 3
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims description 3
- 210000004460 N cell Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 11
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 230000001717 pathogenic effect Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 208000035475 disorder Diseases 0.000 abstract description 3
- 102000005763 Thrombopoietin Receptors Human genes 0.000 description 100
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 100
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 25
- 238000011282 treatment Methods 0.000 description 18
- 102100034195 Thrombopoietin Human genes 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 230000019491 signal transduction Effects 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 10
- 230000001472 cytotoxic effect Effects 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 8
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- -1 viral epitopes Substances 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 6
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 238000004624 confocal microscopy Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 5
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 5
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 5
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 5
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000010199 gene set enrichment analysis Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 102100022749 Aminopeptidase N Human genes 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 4
- 238000003559 RNA-seq method Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- 210000000581 natural killer T-cell Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100035716 Glycophorin-A Human genes 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 102000049320 CD36 Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 102000009058 Death Domain Receptors Human genes 0.000 description 2
- 108010049207 Death Domain Receptors Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 2
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 2
- 102100030385 Granzyme B Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 2
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 2
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000003068 pathway analysis Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002818 protein evolution Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002702 ribosome display Methods 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102100031250 Disks large-associated protein 1 Human genes 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 1
- 101000844784 Homo sapiens Disks large-associated protein 1 Proteins 0.000 description 1
- 101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 description 1
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 description 1
- 101001032341 Homo sapiens Interferon regulatory factor 9 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000026633 IL6 Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 description 1
- 102100038069 Interferon regulatory factor 8 Human genes 0.000 description 1
- 102100038251 Interferon regulatory factor 9 Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 108010052014 Liberase Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Natural products N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000881112 Rattus norvegicus Dual specificity protein phosphatase 12 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 101800001707 Spacer peptide Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000005016 dendritic process Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000007120 differential activation Effects 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 102000054764 human MPL Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000003509 immature nk cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- WLHQHAUOOXYABV-UHFFFAOYSA-N lornoxicam Chemical compound OC=1C=2SC(Cl)=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 WLHQHAUOOXYABV-UHFFFAOYSA-N 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000001939 mature NK cell Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000030716 positive regulation of phosphorylation Effects 0.000 description 1
- 230000016833 positive regulation of signal transduction Effects 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides methods for generating activated natural killer (NK) cells from acute myeloid leukemia (AML) cells. The methods involve contacting the AML cells with a TpoR agonist antibody, and culturing the cell mixture under conditions to allow conversion of the AML cells into NK cells. Also provided in the invention are therapeutic methods of using a pharmaceutical composition containing a TpoR agonist antibody or NK cells described herein for treating various diseases or disorders, e.g., tumors or pathogenic infections. The invention further provides TpoR agonist antibodies that can be employed in these methods.
Description
Methods and Compositions for Producing Activated Natural Killer Cells and Related Uses
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The subject patent application claims the benefit of priority to U.S. Provisional Patent Application Numbers 62/182,386 (filed June 19, 2015) and 62/243,314 (filed October 19, 2015). The full disclosure of the priority applications is incorporated herein by reference in its entirety and for all purposes.
BACKGROUND OF THE INVENTION
[0002] Natural killer cells (NK) cells are cytotoxic lymphocytes and play a role in an innate immune system. NK cells also play a role in adaptive immune response. For example, NK cells can respond to virally infected cells and play a role in the host rejection of tumors. NK cells normally differentiate and mature in the bone marrow, lymph node, spleen, tonsils, and thymus. NK cells contain small granules in their cytoplasm which harbor special proteins such as perforin and proteases known as granzymes. Upon release in close proximity to a cell targeted for killing, perforin forms pores in the cell membrane of the target cell through which the granzymes and associated molecules can enter, inducing apoptosis. One granzyme, granzyme B (also known as granzyme 2 and cytotoxic T- lymphocyte-associated serine esterase 1), is a serine protease crucial for rapid induction of target cell apoptosis in the cell-mediated immune response.
[0003] There is a need in the art for better means for generating activated natural killer cells for direct use in patients. The present invention is directed to this and other unmet needs.
SUMMARY OF THE INVENTION
[0004] In one aspect, the invention provides methods for inducing formation of natural killer (NK) cells from acute myeloid leukemia (AML) cells. The methods entail contacting a population of AML cells with a TpoR agonist antibody under appropriate conditions to
convert the AML cells into NK cells. The TpoR agonist antibody used in the methods has the same binding specificity as that of a TpoR agonist antibody having heavy chain and light chain CDR sequences (HCDRl-3 and LCDRl -3) respectively shown in (1) SEQ ID NOs:4, 5, 21, 7, 25 and 22; (2) SEQ ID NOs:4-7, 25 and 8; (3) SEQ ID NOs:4, 5, 16, 7, 25 and 17; (4) SEQ ID NOs:4, 5, 16, 7, 25 and 18; (5) SEQ ID NOs:4, 5, 19, 7, 25 and 20; or (6) SEQ ID NOs:4, 5, 23, 7, 25 and 24. Also provided by the invention are populations of natural killer (NK) cells generated with these methods.
[0005] In some methods of the invention, the AML cells are cells isolated from a bone marrow sample or a peripheral blood sample of a human AML patient. The AML cells can be from newly diagnosed AML patients or relapsed patients. Some of these methods are directed to generating NK cells from human CD34+ leukemia cells, e.g., human
CD34+/CD33+ leukemia cells or CD34+/CD38- leukemia cells. In some methods, the TpoR agonist antibody comprises heavy chain and light chain CDR sequences (HCDRl -3 and LCDRl-3) that are substantially identical to (1) SEQ ID NOs:4, 5, 21, 7, 25 and 22, respectively; (2) SEQ ID NOs:4-7, 25 and 8, respectively; (3) SEQ ID NOs:4, 5, 16, 7, 25, and 17, respectively; (4) SEQ ID NOs:4, 5, 16, 7, 25 and 18, respectively; (5) SEQ ID NOs:4, 5, 19, 7, 25 and 20, respectively; or (6) SEQ ID NOs:4, 5, 23, 7, 25 and 24, respectively. In some methods, the employed TpoR antibody comprises heavy chain and light chain CDR sequences (HCDRl -3 and LCDRl -3) that are respectively identical to (1) SEQ ID NOs:4, 5, 21 , 7, 25 and 22; (2) SEQ ID NOs:4-7, 25 and 8; (3) SEQ ID NOs:4, 5, 16, 7, 25 and 17; (4) SEQ ID NOs:4, 5, 16, 7, 25 and 18; (5) SEQ ID NOs:4, 5, 19, 7, 25 and 20; or (6) SEQ ID NOs:4, 5, 23, 7, 25 and 24. In some embodiments, the employed TpoR agonist antibody comprises heavy chain and light chain variable region sequences show in (1) SEQ ID NO: 14 and SEQ ID NO: 15, respectively; or (2) SEQ ID NO:2 and SEQ ID NO:3, respectively. In some embodiments, the employed TpoR agonist antibody comprises the scFv 3D9 antibody fragment shown in SEQ ID NO: 12 or SEQ ID NO: l .
[0006] In some embodiments, contacting of the population of AML cells with the TpoR antibody occurs in vitro by culturing the cells in the presence of the TpoR agonist antibody. In some embodiments, the cells are cultured in the presence of the antibody for a period from about 4 days to about 20 days. In some embodiments, the methods of inducing NK cells from AML cells can include an additional step of detecting at least one cellular marker expressed by NK cells. For example, the methods can include detection of the dendritic cell
and NK cell marker CD1 lc, as well as one or more molecules specifically expressed by NK cells (e.g., perforin, granzyme B or interferon γ). In some other embodiments, the contacting of AML cells with the TpoR antibody occurs in vivo in a subject afflicted with acute myeloid leukemia. In some of these embodiments, the TpoR antibody can be engineered to be conjugated to an entity that specifically recognizes a surface antigen of AML cells. In some methods of the invention, the NK cell population induced from AML cells can be further enriched for NK cells to provide a homogenous population of NK cells.
[0007] In another aspect, the invention provides methods for treating acute myeloid leukemia (AML) in a subject. These methods involve administering to the subject a pharmaceutical composition that contains a therapeutic amount of a TpoR agonist antibody having the same binding specificity as that of a TpoR agonist antibody noted above. The subject suitable for treatment with these therapeutic methods can be one that has any subtype of AML or is at various stages of AML. For example, the subject can be afflicted with undifferentiated acute myeloblasts leukemia (M0), acute myeloblasts leukemia with minimal maturation (Ml), acute myeloblasts leukemia with maturation (M2), acute promyelocytic leukemia (APL) (M3), acute myelomonocytic leukemia (M4), acute myelomonocytic leukemia with eosinophilia (M4 eos), acute monocytic leukemia (M5), acute erythroid leukemia (M6), or acute megakaryoblastic leukemia (M7).
[0008] In another aspect, the invention provides methods for treating a cancer or an infection in a subject. The methods entail administering to the subject a pharmaceutical composition that contains a therapeutic amount of a TpoR agonist antibody. The TpoR antibody used in these methods typically has the same binding specificity as that of a TpoR agonist antibody noted above. Some of the methods are directed to treating subjects suffering from blood tumors (e.g., AML). Some of the methods are directed to treating subjects suffering from solid tumors. Some other methods are directed to treating subjects suffering viral infections.
[0009] In another aspect, the invention provides methods for killing leukemia cells (e.g., AML cells or lymphoid tumor cells) in a subject. These methods entail first isolating a population of leukemia cells from the subject. This is followed by treating the isolated cells with a TpoR agonist antibody under conditions sufficient to convert the leukemia cells into NK cells. The TpoR antibody used in these methods typically has the same binding specificity as that of a TpoR agonist antibody noted above. Upon converting the leukemia
cells into NK cells, the NK cells are then administered back to the subject. Some of these methods are directed to killing AML cells in subjects afflicted with AML. In some of these methods, the antibody treated cells are enriched for NK cells prior to being administered back into the subject. Some of these methods further include examining the converted cells for the expression of one or more NK cellular markers, e.g., CD1 lc, perforin, granzyme B and interferon γ.
[0010] In still another aspect, the invention provides novel agonist antibodies for human thrombopoietin receptor (TpoR). Some of these antibodies have the same binding specificity as that of an antibody comprising heavy chain and light chain CDR sequences (HCDRl-3 and LCDRl -3) respectively shown in (1) SEQ ID NOs:4, 5, 21 , 7, 25 and 22; (2) SEQ ID NOs:4, 5, 16, 7, 25 and 17; (3) SEQ ID NOs:4, 5, 16, 7, 25 and 18; (4) SEQ ID NOs:4, 5, 19, 7, 25 and 20; or (5) SEQ ID NOs:4, 5, 23, 7, 25 and 24. Some antibodies of the invention have the same binding specificity as that of a scFv antibody fragment shown in any one of SEQ ID NOs:9-13. Some of these antibodies have heavy chain and light chain CDR sequences that are the same as or substantially identical to (1) SEQ ID NOs:4, 5, 21, 7, 25 and 22, respectively; (2) SEQ ID NOs:4, 5, 16, 7, 25 and 17, respectively; (3) SEQ ID NOs:4, 5, 16, 7, 25 and 18, respectively; (4) SEQ ID NOs:4, 5, 19, 7, 25 and 20,
respectively; or (5) SEQ ID NOs:4, 5, 23, 7, 25 and 24, respectively. Some of the antibodies have heavy chain and light chain variable region sequences show in SEQ ID NO: 14 and SEQ ID NO: 15, respectively.
[0011] A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification and claims.
DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 shows antibody induced differentiation of AML BM cells, a, b show microscopic images of AML BM cells after treatment of PBS or antibody (10 μg/ml) for 4 days. The arrow in the insert box of panel b indicates a cell captured by the differentiated cell, c, d and e are the magnified images of fully differentiated cells in panel b. f shows the differentiated cells by confocal microscopy. The differentiated cells were stained for CD1 lc Nuclei were stained by Hoechst 33342. g and h are enlarged images of the CD1 lc positive differentiated cells.
[0013] Figure 2 shows the immunocytochemistry of early-staged differentiated AML BM cells, a, b and c show the early-staged differentiated cells visualized by confocal microscopy. The differentiated cells were stained for Perforin (green), Interferon g (green) and Granzyme B in a, b and c respectively. F-actin is labeled by rhodamin-phalloidin. Nuclei were stained by Hoechst 33342.
[0014] Figure 3 shows the immunocytochemistry of late-staged differentiated AML BM cells, a, b and c show the late-staged differentiated cells visualized by confocal microscopy. The differentiated cells were stained for Perforin (green), Interferon g (green) and Granzyme B in a, b and c respectively. F-actin is labeled by rhodamin-phalloidin. Nuclei were stained by Hoechst 33342.
[0015] Figure 4 shows SEM analysis of target cell capturing by NK cells, a and c depict the representative SEM images of NK cells which captured AML cells after antibody treatment for 4 days, b is enlarged images of the area boxed in white in a.
|0016J Figure 5 shows AML cells after 4 days culture with PBS, antibody (10 μg/ml) and TPO (10 ng/ml). The inlet of panel b is enlarged images of a differentiated cell in b. d, e and f show the of normal bone marrow CD34+ cells after 4 days culture with PBS, antibody (10 μ^πιΐ) and TPO (10 ng/ml).
[0017] Figure 6 shows de-convoluted images of Figure 2.
[0018] Figure 7 shows de-convoluted images of Figure 3.
[0019] Figure 8 shows activation of signal transduction cascades in AML and normal BM cells after treatment with various doses of antibody or TPO for 1 hr. The
phosphorylation of STAT-3, Akt and Erk was analyzed by western blotting using anti-p- STAT-3, p-Akt and p-ERK antibodies.
[0020] Figure 9 shows cytotoxic activity of the antibody induced differentiated cells. The AML cells were labeled with Calcein-AM and co-cultured with NK cells or
undifferentiated cells. Cells were co-cultured for 4 hrs at 37°C. At the end of the incubation, dead cells were labeled with PI. The percentage of AML cell death was analyzed by a flow cytometer. (A) and (B) indicate different co-culture conditions; AML with NK cells or AML with undifferentiated cells.
[0021] Figure 10 shows antibody induced the differentiation of natural killer (NK) cells from AML cells of relapsed patients. (A) and (B) represent untreated AML cells and antibody induced NK cells. (C) to (E) show the magnified induced NK cells. The
differentiated cells were stained for perforin, interferon γ or granzyme B in (A), (B) or (Q respectively. Nuclei were stained by Hoechst 33342. F-actin is labeled by rhodamin- phalloidin.
[0022] Figure 1 1 shows antibody induced NK cells killed AML cells. (A) and (B) describes the NK cells capturing target cells (white arrow). The differentiated cells were stained for perforin, interferon γ or granzyme B in (A), (B). Nuclei were stained by Hoechst 33342. F-actin is labeled by rhodamin-phalloidin.
[0023] Figure 12 shows TPOR signal activation by antibody in relapsed AML cells. (A). After treatment with various doses of antibody or 10 ng/ml of TPO for 1 hr, the
phosphorylation of AKT and ERK was analyzed by western blotting using anti-p-AKT and p-ERK antibodies. (B). The TPOR signaling was tested at various times after antibody or TPO treatment.
[0024] Figure 13 shows cytotoxic activity of the antibody induced NK cells from both newly diagnosed AML cells and relapsed AML cells. NK cells were respectively induced from relapsed AML cells and newly diagnosed AML cells with the 3D9 TpoR antibody for 4 days. Then undifferentiated AML cells were added and incubated for 24 hrs. To measure the cell viability, MTS solution was added to each well and absorbance were measured.
[0025] Figure 14 shows comparison of the efficacy of antibody with 5 affinity maturated variants. The wild type 3D9 antibody and 5 variants were applied to relapsed AML cells to induce the differentiation of NK cells. The box in the upper left panel shows the magnified NK cells after differentiation.
DETAILED DESCRIPTION OF THE INVENTION
I. Overview
[0026] The recent discovery of many agonist antibodies that govern cell fates has opened the way to induce selectively a large variety of specific cells of the immune system from normal or malignant bone marrow or blood. Often these agonist antibodies induce cell differentiation along lineages expected from the known function of the receptor to which they bind. In other cases, they activate differentiation or trans-differentiation pathways that are different from what would be expected from the nature of the receptor with which they interact.
[0027] The present invention is predicated in part on the discovery by the present inventors that a thrombopoietin receptor (TpoR) agonist antibody induces efficiently highly activated NK cells from malignant human bone marrow (BM) and peripheral blood of several different AML patients. Specifically, primary human AML cells were exposed to the TpoR agonist antibody 3D9 (which was described in WO2014/035693) for about 4 days. Approximately 80% of the cells attached to the well and adopted a morphology
characterized by extension of long dendrites (Figure 1). The morphology was similar to that of dendritic cells (DC) or NK cells. The inventors then analyzed cell markers using antibodies against marker molecules such as CDl lc, Perforin, Interferon-γ and Granzyme B. CDl lc is highly expressed in both DC and NK cells, and the other markers are mainly expressed in NK cells. As detailed herein, it was found that the induced cells were positively stained for all of these markers. These results strongly indicate that the differentiated cells are NK cells. In addition, it was observed that the antibody stimulated canonical TpoR signal transduction cascades, namely the phosphorylation of STAT-5, Akt and Erk in the TpoR Ab-treated AML cells (Figure 8). Furthermore, the inventors observed that the induced NK-like cells made contact with sister AML cells via dendritic processes, resulting in destruction of non-differentiated AML cells. Other than the 3D9 TpoR agonist antibody, the inventors also generated several variants from 3D9. These variants were found to also possess the ability in inducing NK formation from AML cells.
[0028] The invention accordingly provides methods of using the 3D9 TpoR agonist antibody and derivatives thereof for inducing formation of NK cells from AML cells. The invention also provides therapeutic applications of the TpoR agonist antibodies described herein for treating various diseases or conditions, e.g., cancers such as AML. From a therapeutic standpoint, the ability to induce activated NK cells from the readily accessible peripheral blood and bone marrow cellular compartments opens new routes to cancer therapy that are much simpler than those currently available in the art. Also provided in the invention are TpoR agonist antibodies that can be employed in the practice of the various methods described herein.
II. Definitions
[0029] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this
invention pertains. The following references provide one of skill with a general definition of many of the terms used in this invention: Academic Press Dictionary of Science and Technology, Morris (Ed.), Academic Press (1st ed., 1992); Oxford Dictionary of
Biochemistry and Molecular Biology, Smith et al. (Eds.), Oxford University Press (revised ed., 2000); Encyclopaedic Dictionary of Chemistry, Kumar (Ed.), Anmol Publications Pvt. Ltd. (2002); Dictionary of Microbiology and Molecular Biology, Singleton et al. (Eds.), John Wiley & Sons (3rd ed., 2002); Dictionary of Chemistry, Hunt (Ed.), Routledge (1st ed., 1999); Dictionary of Pharmaceutical Medicine, Nahler (Ed.), Springer-Verlag Telos (1994);
Dictionary of Organic Chemistry, Kumar and Anandand (Eds.), Anmol Publications Pvt. Ltd. (2002); &ηά Α Dictionary of Biology (Oxford Paperback Reference), Martin and Hine (Eds.), Oxford University Press (4th ed., 2000). In addition, the following definitions are provided to assist the reader in the practice of the invention.
[0030] Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, acute myeloblasts leukemia, or acute nonlymphocytic leukemia (ANLL), is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.
[0031] The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.
[0032] AML has several subtypes; treatment and prognosis varies among subtypes. Five- year survival varies from 15-70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant.
Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.
[0033] The term "antibody" or "antigen-binding fragment" refers to polypeptide chain(s) which exhibit a strong monovalent, bivalent or polyvalent binding to a given antigen, epitope or epitopes. Unless otherwise noted, antibodies or antigen-binding fragments used in the invention can have sequences derived from any vertebrate, camelid, avian or pisces species. They can be generated using any suitable technology, e.g., hybridoma technology, ribosome display, phage display, gene shuffling libraries, semi-synthetic or fully synthetic libraries or combinations thereof. Unless otherwise noted, the term "antibody" as used in the present invention includes intact antibodies, antigen-binding polypeptide fragments and other designer antibodies that are described below or well known in the art (see, e.g., Serafini, J Nucl. Med. 34:533-6, 1993).
[0034] An intact "antibody" typically comprises at least two heavy (H) chains (about 50- 70 kD) and two light (L) chains (about 25 kD) inter-connected by disulfide bonds. The recognized immunoglobulin genes encoding antibody chains include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
[0035] Each heavy chain of an antibody is comprised of a heavy chain variable region (VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CHI, C m and C m. Each light chain is comprised of a light chain variable region (VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system and the first component (Clq) of the classical complement system.
[0036] The VH and VL regions of an antibody can be further subdivided into regions of hypervariability, also termed complementarity determining regions (CDRs), which are interspersed with the more conserved framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1 , CDR1, FR2, CDR2, FR3, CDR3, FR4. The locations of CDR and FR regions and a numbering system have been defined by, e.g., Kabat et al., Sequences
of Proteins of Immunological Interest, U.S. Department of Health and Human Services, U.S. Government Printing Office (1987 and 1991).
[0037] Antibodies to be used in the invention also include antibody fragments or antigen-binding fragments which contain the antigen-binding portions of an intact antibody that retain capacity to bind the cognate antigen. Examples of such antibody fragments include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an intact antibody; (v) disulfide stabilized Fvs (dsFvs) which have an interchain disulfide bond engineered between structurally conserved framework regions; (vi) a single domain antibody (dAb) which consists of a VH domain (see, e.g., Ward et al., Nature 341 :544-546, 1989); and (vii) an isolated complementarity determining region (CDR).
[0038] Antibodies suitable for practicing the present invention also encompass single chain antibodies. The term "single chain antibody" refers to a polypeptide comprising a VH domain and a VL domain in polypeptide linkage, generally linked via a spacer peptide, and which may comprise additional domains or amino acid sequences at the amino- and/or carboxyl-termini. For example, a single-chain antibody may comprise a tether segment for linking to the encoding polynucleotide. As an example, a single chain variable region fragment (scFv) is a single-chain antibody. Compared to the VL and VH domains of the Fv fragment which are coded for by separate genes, a scFv has the two domains joined (e.g., via recombinant methods) by a synthetic linker. This enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules.
[0039] Antibodies that can be used in the practice of the present invention also encompass single domain antigen-binding units which have a camelid scaffold. Animals in the camelid family include camels, llamas, and alpacas. Camelids produce functional antibodies devoid of light chains. The heavy chain variable (VH) domain folds
autonomously and functions independently as an antigen-binding unit. Its binding surface involves only three CDRs as compared to the six CDRs in classical antigen-binding molecules (Fabs) or single chain variable fragments (scFvs). Camelid antibodies are capable of attaining binding affinities comparable to those of conventional antibodies.
[0040] The various antibodies or antigen-binding fragments described herein can be produced by enzymatic or chemical modification of the intact antibodies, or synthesized de novo using recombinant DNA methodologies, or identified using phage display libraries. Methods for generating these antibodies or antigen-binding molecules are all well known in the art. For example, single chain antibodies can be identified using phage display libraries or ribosome display libraries, gene shuffled libraries (see, e.g., McCafferty et al., Nature 348:552-554, 1990; and U.S. Pat. No. 4,946,778). In particular, scFv antibodies can be obtained using methods described in, e.g., Bird et al., Science 242:423-426, 1988; and Huston et al„ Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988. Fv antibody fragments can be generated as described in Skerra and Pluckthun, Science 240: 1038-41, 1988. Disulfide- stabilized Fv fragments (dsFvs) can be made using methods described in, e.g., Reiter et al., Int. J. Cancer 67: 1 13-23, 1996. Similarly, single domain antibodies (dAbs) can be produced by a variety of methods described in, e.g., Ward et al., Nature 341 :544-546, 1989; and Cai and Garen, Proc. Natl. Acad. Sci. USA 93:6280-85, 1996. Camelid single domain antibodies can be produced using methods well known in the art, e.g., Dumoulin et al., Nature Struct. Biol. 11 :500-515, 2002; Ghahroudi et al, FEBS Letters 414:521-526, 1997; and Bond et al, J Mol Biol. 332:643-55, 2003. Other types of antigen-binding fragments (e.g., Fab, F(ab')2 or Fd fragments) can also be readily produced with routinely practiced immunology methods. See, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1998.
[0041] The term "contacting" has its normal meaning and refers to combining two or more agents (e.g., polypeptides or phage), combining agents and cells, or combining two populations of different cells. Contacting can occur in vitro, e.g., mixing two polypeptides or mixing a population of antibodies with a population of cells in a test tube or growth medium. Contacting can also occur in a cell or in situ, e.g., contacting two polypeptides in a cell by coexpression in the cell of recombinant polynucleotides encoding the two polypeptides, or in a cell lysate.
[0042] The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same. Two sequences are "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity over a specified region,
or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length.
[0043] Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 2:482c, 1970; by the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443, 1970; by the search for similarity method of Pearson and Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444, 1988; by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, WI); or by manual alignment and visual inspection (see, e.g., Brent et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (ringbou ed., 2003)). Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al, Nuc. Acids Res. 25:3389-3402, 1977; and Altschul et al, J. Mol. Biol. 215:403-410, 1990, respectively.
[0044] A "ligand" is a molecule that is recognized by a particular antigen, receptor or target molecule. Examples of ligands that can be employed in the practice of the present invention include, but are not restricted to, agonists and antagonists for cell membrane receptors, toxins and venoms, viral epitopes, hormones, hormone receptors, polypeptides, peptides, enzymes, enzyme substrates, cofactors, drugs (e.g. opiates, steroids, etc.), lectins, sugars, polynucleotides, nucleic acids, oligosaccharides, proteins, and monoclonal antibodies.
[0045] Natural killer cells, or NK cells, are a type of cytotoxic lymphocyte critical to the innate immune system. The role NK cells play is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells provide rapid responses to viral-infected cells and respond to tumor formation, acting at around 3 days after infection. Typically, immune cells detect major histocompatibility complex (MHC) presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis. NK cells are unique,
however, as they have the ability to recognize stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction. They were named "natural killers" because of the initial notion that they do not require activation to kill cells that are missing "self markers of MHC class 1. This role is especially important because harmful cells that are missing MHC 1 markers cannot be detected and destroyed by other immune cells, such as T lymphocyte cells.
[0046] NK cells of the invention contain cytoplasmic markers such as CD1 lc, Perforin, Interferon-γ and Granzyme B. NK cells differ from natural killer T cells (NKTs) phenotypically, by origin and by respective effector functions. NKT cell activity promotes NK cell activity by secreting IFNy. In contrast to NKT cells, NK cells do not express T-cell antigen receptors (TCR) or pan T marker CD3 or surface immunoglobulins (Ig) B cell receptors, but they usually express other specific surface markers such as CD16 (FcyRIII) and CD56 in humans.
[0047] Unless otherwise noted, the term "receptor" broadly refers to a molecule that has an affinity for a given ligand. Receptors may-be naturally-occurring or manmade molecules. Also, they can be employed in their unaltered state or as aggregates with other species. Receptors may be attached, covalently or noncovalently, to a binding member, either directly or via a specific binding substance. A typical example of receptors which can be employed in the practice of the invention is cell surface signaling receptor.
[0048] The term "subject" refers to human and non-human animals (especially non- human mammals). In addition to human, it also encompasses other non-human animals such as cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys.
[0049] The term "target," "target molecule," or "target cell" refers to a molecule or biological cell of interest that is to be analyzed or detected, e.g., a ligand such as a cytokine or hormone, a polypeptide, a cellular receptor or a cell.
[0050] A cell has been "transformed" by exogenous or heterologous polynucleotide when such polynucleotide has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming polynucleotide may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming polynucleotide has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This
stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming polynucleotide. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth in vitro for many generations.
III. Thrombopoietin receptor (TpoR) agonist antibodies
[0051] The invention provides novel methods that allow one to convert AML cells into natural killer cells via the use of a thrombopoietin receptor (TpoR) agonist antibody. The TpoR agonist antibody used in the methods has the same binding specificity as that of a specific TpoR antibody known in the art. The structural information of this TpoR antibody, 3D9, was described in detail in the literature, e.g., Zhang et al., Chem. Biol., 20: 734-741, 2013; and WO2014/035693. This scFv antibody has an amino acid sequence shown in SEQ ID NO: 1. The sequences of the heavy chain and the light chain portions of the scFv are respectively shown in SEQ ID NOs:2 and 3. The CDR sequences of the heavy chain variable region of this antibody are RDTFNTYG (CDR1 ; SEQ ID NO:4), IIPIFGTA (CDR2; SEQ ID NO:5), and CARDRKLGGSDYW (CDR3; SEQ ID NO:6). The CDR sequences of its light chain variable region are QGLGRW (CDR1 ; SEQ ID NO:7), AAS (CDR2; SEQ ID NO:25), and QQSNSFPWT (CDR3; SEQ ID NO:8).
[0052] TpoR agonist antibodies used in the invention are preferably monoclonal antibodies like the antibodies exemplified in the Examples below. In general, the antibodies have the same binding specificity as that of the 3D9 TpoR agonist antibody. These antibodies should compete with the 3D9 antibody for binding to the TpoR receptor. The TpoR agonist antibodies suitable for the invention need not possess exactly the same functional properties as that of the 3D9 antibody, e.g., activities in activating the TpoR signaling pathway. In addition to containing variable regions sequences derived from the 3D9 antibody, some agonist antibodies of the invention can also contain other antibody sequences fused to the variable region sequences. For example, the antibodies can contain an Fc portion of IgG. The antibodies can also be conjugated, covalently or noncovalently, to another entity that specifically targets a surface antigen or marker on AML cells. The TpoR agonist antibody can also be part of a bispecific antibody that recognizes both the TpoR and a specific target antigen or epitope on the AML cells.
[0053] Some TpoR agonist antibodies for practicing the invention harbor variable region sequences that are substantially identical to that of the 3D9 antibody. Some other TpoR agonist antibodies have all CDR sequences in their variable regions of the heavy chain and light chain respectively identical to the corresponding CDR sequences of the 3D9 TpoR agonist antibody. In still some other embodiments, the TpoR antibody has its entire heavy chain and light chain variable region sequences respectively identical to the corresponding variable region sequences of the 3D9 antibody. In some other embodiments, other than the identical CDR sequences, the antibodies contain amino acid residues in the framework portions of the variable regions that are different from the corresponding amino acid residues of the 3D9 antibody. Relative to the 3D9 antibody, the agonist TpoR antibodies suitable for the invention can undergo non-critical amino-acid substitutions, additions or deletions in the variable region without loss of binding specificity or effector functions, or intolerable reduction of binding affinity or receptor agonizing activities. Usually, antibodies incorporating such alterations exhibit substantial sequence identity to the 3D9 TpoR antibody. For example, the mature light chain variable regions of some of the TpoR agonist antibodies for use in the invention have at least 75% or at least 85% sequence identity to the sequence of the mature light chain variable region of the 3D9 antibody. Similarly, the mature heavy chain variable regions of the antibodies typically show at least 75% or at least 85%) sequence identity to the sequence of the mature heavy chain variable region of the 3D9 antibody. In various embodiments, the antibodies typically have their entire variable region sequences that are substantial identical (e.g., 75%, 85%, 90%, 95%, or 99%) to the corresponding variable region sequences of the 3D9 antibody. Some TpoR agonist antibodies for use in the invention have the same specificity but improved affinity or receptor-agonizing activities if compared with the 3D9 antibody.
[0054] General methods for preparation of monoclonal or polyclonal antibodies are well known in the art. See, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1998; Kohler & Milstein, Nature 256:495-497, 1975; Kozbor et al., Immunology Today 4:72, 1983; and Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy, 1985.
IV. Converting AML cells into natural killer cells
[0055] The TpoR agonist antibodies described above can induce AML or other leukemia cells to become NK cells. Acute myeloid leukemia (AML) is a malignant disease characterized by a disruption in normal hematopoietic differentiation and the accumulation of abnormal, immature myeloid cells in the bone marrow and peripheral blood. In general, determination and classification of AML can be based on the two well-known systems that have been used to classify AML into subtypes, the French-American-British (FAB) classification and the newer World Health Organization (WHO) classification. For example, under the FAB classification, AML subtypes include undifferentiated acute myeloblasts leukemia (MO), acute myeloblasts leukemia with minimal maturation (Ml), acute myeloblasts leukemia with maturation (M2), acute promyelocytic leukemia (APL) (M3), acute myelomonocytic leukemia (M4), acute myelomonocytic leukemia with eosinophilia (M4 eos), acute monocytic leukemia (M5), acute erythroid leukemia (M6), and acute megakaryoblastic leukemia (M7). Subtypes MO through M5 all start in immature forms of white blood cells. M6 AML starts in very immature forms of red blood cells, while M7 AML starts in immature forms of cells that make platelets. In addition to AML cells, other blood tumor cells (e.g., lymphoid tumor cells) may also be used in the practice of the invention.
[0056] Some embodiments of the invention are directed to converting AML cells into NK cells. AML cells of any subtypes can be used in the practice of the invention.
Molecular markers known to be present on the different subtypes of AML cells are useful for their isolation and evaluation. A non-exhaustive list of antigen markers for AML cells include CD34, CD1 17, CD38, and HLA-DR (for progenitor AML cells); CD13, CD33, CD15, and MPO (for myeloid AML cells); CD33, CD14, CD64, and CD36 (for monocytic AML cells); CD235a and CD71 (for erythroid AML cells); CD41 and CD61 (for megakaryocytic AML cells); and CD 19, CD79a, CD 10, and cytoplasmic CD3 (for lymphoid AML cells). Advances in molecular genetics have identified additional markers that may be useful for diagnosing AML and identifying leukemic stem cells. Thus, increased expression of cell surface markers such as TIM-3, IL-3 R alpha (CD123), and CD44 can be used to distinguish normal CD34+CD38- hematopoietic stem cells and the subpopulation of leukemic stem cells. In addition, monoclonal antibodies targeted against leukemic stem cell
surface antigens such as CD44, CD47, and IL-3 R alpha, have demonstrated efficacy in the treatment of AML in animal models.
[0057] AML cells used in the practice of the invention can be prepared from either a BM sample or a blood sample of the AML patients. These include samples from peripheral blood, bone marrow fluid, umbilical blood, and etc. Leukemic cells from patient blood samples can be obtained by separating plasma from blood, by a known method, for example, a density gradient centrifugation method. Some methods of the invention utilize CD34+ leukemic cells. In addition to CD34+, the AML cells typically harbor one or more other surface markers of myeloid cells. For example, CD13 and CD33 are markers for cells of myeloid origin. In some embodiments, the AML cells used in the methods can include human CD34+/CD33+ leukemia cells (e.g., CD34+/CD33+/CD13+ cells). In some embodiments, the cell population for inducing NK cells includes CD34+/CD38- cells. As noted above, increased expression of cell surface markers such as TIM-3, IL-3 R alpha (CD 123), and CD44 can be used to distinguish normal CD34+CD38- hematopoietic stem cells and the subpopulation of leukemic stem cells.
[0058] The AML cell containing samples can be maintained and cultured in any physiologically-acceptable solution suitable for the collection and/or culture of the cells. These include, e.g., a saline solution (e.g., phosphate-buffered saline, Kreb's solution, modified Kreb's solution, Eagle's solution, 0.9% NaCl, etc.), and a culture medium (e.g., DMEM, H.DMEM, etc.), and the like. The solution can contain one or more tissue- degrading enzymes, e.g., a metalloprotease, a serine protease, a neutral protease, a hyaluronidase, an RNase, or a DNase, or the like. Such enzymes include, but are not limited to, collagenases (e.g., collagenase I, II, III or IV, a collagenase from Clostridium
histolyticum, etc.); dispase, thermolysin, elastase, trypsin, LIBERASE, hyaluronidase, and the like. The solution can further include a bacteriocidally or bacteriostatically effective amount of an antibiotic. Examples of suitable antibiotics include a macrolide (e.g., tobramycin), a cephalosporin (e.g., cephalexin, cephradine, cefuroxime, cefprozil, cefaclor, cefixime or cefadroxil), a clarithromycin, an erythromycin, a penicillin (e.g., penicillin V) or a quinolone (e.g., ofloxacin, ciprofloxacin or norfloxacin), a tetracycline, a streptomycin, and etc.
[0059] The culture of a cell population in the presence of the TpoR agonist antibody can be performed in accordance with standard cell culturing protocols well known in the art.
Some specific procedures for generating NK cells from an AML cell population are exemplified herein. Typically, the isolated AML cells are contacted with an effective amount of an antibody having the same binding specificity as that of 3D9 TpoR agonist antibody under appropriate conditions to facilitate the conversion. In some embodiments, the antibody is contacted with the cells in vitro. In these embodiments, the cell population can be cultured at a concentration of about lxl O2, lxlO3, lxl O4, lxlO5, lxlO6, lxlO7, lxlO8 cells/ml or higher. As exemplified herein, the AML cells can be cultured in the presence of an effective amount of the antibody, e.g., at a concentration of 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, 10, 25, 50, 100 μg/ml or higher. The contacting can last for a sufficient period of time, e.g., at least 12 hours, 1 day, 2 days, 4 days, 6 days, 10 days, 25 days, 50 days, 75 days, 100 days or longer. In some of these embodiments, the cells can be examined along the process for molecular markers and/or morphology indicative of the presence of NK cells. As demonstrated herein, the cells can be analyzed for the presence of CDl lc, interleukin γ, perforin and granzyme B. This can be achieved, e.g., by staining with the appropriate antibodies and visual inspection via confocal microscopy as exemplified herein.
[0060] The presence of NK cells in the induced cell population can also be analyzed by detecting many other NK specific markers well known in the art. In some embodiments, properties of the induced cells can be assessed by detecting the presence of other NK cell- specific markers, e.g., CD56, CD94, CDl 17 and NKp46. This can be accomplished by routinely practiced techniques, e.g., by flow cytometry. In some other embodiments, NK cell properties of the induced cells can be examined by the morphological characteristics of NK cells, e.g., large size, high protein synthesis activity in the abundant endoplasmic reticulum (ER), and/or preformed granules. In some embodiments, maturation of NK cells can be assessed by detecting one or more functionally relevant makers, for example, CD94, CDl 61, NKp44, DNAM-1 , 2B4, NKp46, CD94, KIR, and the NKG2 family of activating receptors (e.g., NKG2D). Maturation of NK cells can also be assessed by detecting specific markers during different developmental stages. In some embodiments, the induced cells contain pro-NK cells that are CD34+, CD45RA+, CD10+, CDl 17-, and/or CD161 - cells. In some embodiments, the induced cells contain pre-NK cells that are CD34+, CD45RA+, CD10-, CDl 17+, and/or CD161 - cells. In other embodiments, the induced cells contain immature NK cells that are CD34-, CDl 17+, CDl 61+, NKp46-, and/or CD94/NKG2A- cells. In still some other embodiments, the induced cells contain NK cells that are CDl 17+,
NKp46+, CD94 N G2A+, CD16-, and/or KIR+/-. In some embodiments, the induced cells contain NK cells that are CD1 17-, NKp46+, CD94/NKG2A+/-, CD 16+, and/or IR+. In some other embodiments, maturation of NK cells can be determined by the percentage of NK cells that are CD 161-, CD94+ and/or NKp46+. In some embodiments, the induced cell population contains at least 10%, 20%, 25%, 30%, 35%, 40%, 50%, 55%, 60%, 65% or 70% of mature NKp46+ NK cells, mature CD94+ NK cells, or mature CD161 - cells. In various embodiments, expression of these markers can be detected and quantified via standard immunological assays using, e.g., antibodies to one or more of these cell markers. The antibodies can be conjugated to a detectable label, e.g., a fluorescent label, to facilitate detection and quantitation.
[0061] In some embodiments, the TpoR agonist antibody is contacted with the AML cells or other tumor cells (e.g., lymphoid tumor cells) in vivo. For example, as detailed herein, a therapeutically effective amount of the antibody can be administered to a subject afflicted with AML or another type of tumor (e.g., another blood tumor). In some other embodiments, subjects with AML or other tumors can be treated ex vivo. In these methods, AML cells are first isolated from the subjects and contacted with the TpoR agonist antibody to generate NK cells. The induced NK cells are then reintroduced into the subjects.
Preferably, the AML cells to be treated with the TpoR agonist antibody are obtained from the same subject into whom the resulting NK cell population will be administered.
[0062] In some embodiments, the AML cells isolated from AML patients can be treated with one or more stimulating cytokines such as GM-CSF, IL-2, IL-4 and TNFa prior to, simultaneously with, or subsequent to being contacted with the TpoR agonist antibody. The concentration of each of the cytokines in the culture medium can be in the range of, e.g., about 0.01 to 1 x 10s U/ml. The culture medium can further contain serum or plasma. The amount of serum or plasma can be present at concentration of, e.g., about 0 to 20% by volume, preferably more than 0 to 10% by volume.
[0063] The cell culture may be performed under known culture conditions, and the conditions which are used in normal cell culture can be applied. For example, culture can be performed under the conditions of 37°C and 5% C02. Cells can be diluted by adding a fresh medium to a cell culture liquid at a suitable time interval, a medium can be exchanged with a fresh medium, or a cell culture instrument can be exchanged. The culturing period for converting the AML cells into NK cells can be, e.g., from 1 to 100 days, 2 to 75 days, 3-50
days, or 4-25 days. In some embodiments, the AML cells are cultured in the presence of the TpoR antibody and other agents for a period of around 4 days, 5 days, 6 days, 7 days, or 8 days. Any cell culture instrument can be used in the invention. These include, e.g., a petri dish, a flask, a bag, a bioreactor etc. can be used. For cell culture bags, a C02 gas permeable bag for cell culture can be used. When a large amount of cells are being treated, use of a bioreactor is advantageous. Although the cell culturing can be performed in either an open system or a closed system, it is preferable to perform the culturing in a closed system from a view point of safety of the resulting NK cells.
V. Therapeutic applications
[0064] The invention provides methods of treating cancer and other diseases via the use of TpoR agonist antibodies described herein to induce formation of NK cells. The ability to induce some members of an AML cell population to become NK cells which in turn can kill other members of the AML cell population is particularly beneficial for therapeutic applications. It is a dynamic process at the population level where a uniform population of cancer cells is converted to a mixture of targets and killers. In effect, the cancer cells kill one another and since any member of the clonal population can be converted to a killer cell. With sufficient time, the entire malignant cell population or clone can be eliminated.
Accordingly, in some embodiments of the invention, a pharmaceutical composition containing one of the TpoR agonist antibodies described herein is administered to patients so that the converted NK cells can recognize and kill the neighboring diseased cells. In some of these embodiments, a recognition element such as an antibody can be expressed on the cell surface to provide more specific and/or stronger cytotoxicity. In some other embodiments, NK cell populations induced with the TpoR antibody and further enriched in vitro can be administered to subjects suffering from cancers or other diseases, e.g., AML, other blood tumors, solid tumors and viral infections. The pharmaceutical composition of the invention can be used alone or in combination with other known agents in the art for treating cancer or pathogenic infections.
[0065] NK cells produced by the method of the present invention and a composition containing the same may be used for treatment of cancers and infectious diseases. NK cells produced by the method of the present invention may be applied to all types of cancers, including solid cancer and blood cancer. As used herein, the term "solid cancer" refers to
mass-type cancer formed in an organ, unlike blood cancer. Cancers developed in most of organs correspond to solid cancers. In addition to blood cancer such as AML, cancers which can be treated using the TpoR antibody- or NK cell-containing compositions of the present invention also include solid cancer such as stomach cancer, liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain cancer,
neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, lymphoma and so on. In some other embodiments, the therapeutic compositions of the invention are used for treating infectious diseases, e.g., viral infections. As used herein, the term "infectious diseases" is means to include all diseases which are caused by infection with viruses or pathogenic bacteria and can be infected through respiratory organ, blood or skin contact. Non-limiting examples of such infectious diseases include, but are not limited to, hepatitis B, hepatitis C, human papilloma virus (HPV) infection, cytomegalovirus infection, viral respiratory disease, influenza and so on.
[0066] In some embodiments, the methods of the invention are used for treating blood tumors such as leukemia. Leukemia is cancer of the blood cells, usually affecting the white blood cells. Leukemia can occur in either the lymphoid or myeloid white blood cells.
Cancer that develops in the lymphoid cells is called lymphocytic leukemia. Cancer that develops in the myeloid cells is called myelogenous leukemia. The disease can be either acute (begins abruptly and is usually short lived) or chronic (persists for a long period of time). Based on these findings, leukemia is then classified into one of the four main types of leukemia: acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphocytic leukemia (ALL), or chronic lymphocytic leukemia (CLL). The methods described herein can be used to convert any of the leukemia cells into NK cells and to treat subjects afflicted with any of these blood tumors.
[0067] In one aspect, the invention provides therapeutic applications of the TpoR agonist antibodies described herein for inducing NK cells in subjects suffering from various diseases or disorders. In some embodiments, the TpoR agonist antibody can be employed to treat subjects afflicted with a condition that is manifested by the presence of AML cells or lymphoid tumor cells. In these therapeutic methods, the TpoR antibody, preferably in a pharmaceutical composition, is directly administered to subjects in need of treatment. Upon contacting the antibody with AML cells in vivo, NK cells can be induced which in turn can
exert cytotoxic activities against neighboring non-induced AML cells and other diseased cells. In some embodiments, the antibody can be conjugated to a moiety that specifically recognizes a surface marker on the AML cells to facilitate targeted delivery of the TpoR antibody, e.g., a ligand for an AML specific surface marker described herein. In some embodiments, a bispecific antibody comprised of the antigen-binding site of the TpoR agonist antibody and also the antigen-binding site of a second antibody recognizing an AML specific surface marker can be used. Such immune conjugates or bispecific antibodies can be generated using standard procedures routinely practiced in the art.
[0068] As described above, some embodiments of the invention are directed to ex vivo treatment of subjects suffering from cancers or other diseases. For example, a subject afflicted with a blood tumor (e.g., AML or lymphoid tumors) can be treated by administering NK cell population generated in vitro from tumor cells that are isolated from the same subject. This is followed by treating the isolated cells with a TpoR agonist antibody described herein that can convert the tumor cells into NK cells. Thereafter, the NK cells generated in vitro are reintroduced into the subject to kill leukemia cells (e.g., AML cells) that remain in the subject. In these embodiments, a population of leukemia cells (e.g., AML cells) is first isolated from the subject. The population should contain tumor cells for converting into NK cells that are sufficient for subsequent treatment. In various
embodiments, the isolated cell population should contain at least lxlO2, lxlO3, lxlO4, lxlO5, lxl O6, lxl O7 or more leukemia cells. In some embodiments, the cell population treated with the antibody is further enriched for NK cells. This allows the generation of a more homogenous population of NK cells to enhance therapeutic efficacy. In some of these embodiments, the treated cell population can be examined for expression of one or more cellular markers indicative of NK cells. For example, the cells can be analyzed for the expression of NK marker CD1 lc, as well as additional markers such perforin, granzyme B and interferon γ.
[0069] Also provided in the invention are NK cell populations generated in vitro by the methods described herein and therapeutic applications of such NK cell populations. For therapeutic applications of the NK cell populations, the induced cell population is preferably enriched for NK cells. NK cells can be first isolated from the induced cell population noted above, and then administered to a subject in need of treatment of a disease or disorder (e.g., tumor or viral infection). Isolation and enrichment of natural killer cells from the induced
cell population can be readily carried out with methods well known in the art. For example, activated NK cells can be isolated or selected for cells expressing NK specific markers exemplified herein, e.g., perforin, interferon gamma, and granzyme B. Enrichment can also include staining cells from the induced cell population or previously NK selected cells with antibodies recognizing NK specific markers, e.g., CD56 and CD3, and selecting for CD56+ CD3- cells. Commercially available kit, e.g., the NK Cell Isolation Kit (Miltenyi Biotec) can be employed. The NK cells can also be isolated or enriched by removal of cells other than NK cells in the induced cell population. For example, NK cells may be isolated or enriched by depletion of cells displaying non-NK cell markers using, e.g., antibodies to one or more of CD3, CD4, CD14, CD19, CD20, CD36, CD66b, CD123, HLA DR and/or CD235a (glycophorin A). Negative isolation can be carried out using a commercially available kit, e.g., the NK Cell Negative Isolation Kit (Dynal Biotech). Cells isolated by these methods may be additionally sorted, e.g., to separate CD16+ and CD16- cells. Cell separation can be accomplished by, e.g., flow cytometry, fluorescence-activated cell sorting (FACS) or magnetic cell sorting using microbeads conjugated with specific antibodies. Upon enrichment, the NK cell populations of the invention typically contain at least 50%, 60%, 70%, 80%, 90%, 92%, 94%, 96%, 98% of homogeneous or heterogeneous NK cells that express the NK specific markers described herein.
[0070] The NK populations of the invention can be administered allogeneically or autologously to subjects for enhanced cytotoxicity. In some embodiments, the cytotoxic activity of the cells can be first examined in vitro prior to administration to subjects. This can be performed by, e.g., cytotoxicity assays using a target cell such as a cultured tumor cell (AML cell or other types of tumor cells). The cell population can then be administered to subjects with conditions that can benefit from enhanced cytotoxic activity provided by the administered NK cells, e.g., solid tumors and viral infections. In some embodiments, the cytotoxicity of the administered NK cell population can be enhanced by treatment or coadministration of the cell population with a suitable cytokine, e.g., IFN-a. Such treated cell population can exert enhanced cytotoxicity against various cancer cells. In some
embodiments, the administered NK cells can be engineered to express a molecule having affinity for a target molecule (e.g., T cell receptor, antibody, receptor etc.), a cell surface antigen, an enzyme, a signal transduction molecule (e.g. cytokine), or a functional domain thereof (e.g. a variable region of an antibody or TCR, a single-chain antibody, a signaling
domain of a receptor). For example, for targeted delivery of the NK cells to tumors or pathogens, the isolated NK cells can be further modified by expressing a moiety (e.g., an antibody) on the cell surface that specifically recognizes an antigen of a tumor cell or a pathogen.
[0071] The invention additionally provides kits or pharmaceutical combinations for converting AML cells into NK cells. The kits typically contain one or more TpoR agonist antibodies described herein, tools and materials for isolating AML cells from a subject, and reagents for co-culturing AML cells with the TpoR antibody. In some embodiments, the kits can contain the TpoR antibody and a cultured AML cell population for generating NK cells that can be applied allogeneically to subjects afflicted with tumors or pathogenic infections.
[0072] The pharmaceutical compositions containing a TpoR agonist antibody or a NK cell population described herein can be administered to subjects in need of treatment in accordance with standard procedures of pharmacology. Methods of administering the therapeutic compositions to a subject can be accomplished based on procedures routinely practiced in the art. See, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Co., 20th ed., 2000; Ritter et al., J. Clin. Invest. 116:3266-76, 2006; Iwasaki et al., Jpn. J. Cancer Res. 88:861-6, 1997; Jespersen et al., Eur. Heart J. 1 1 :269-74, 1990; and Martens, Resuscitation 27: 177, 1994. For example, a composition containing the induced NK cells are typically administered (e.g., via injection) in a physiologically tolerable medium, such as phosphate buffered saline (PBS). The isolated cells, or their engineered form as disclosed herein, should be administered to the subject in a number sufficient to inhibit the development of the disease (e.g., growth of a tumor) in the subject. In some embodiments, administration of therapeutic composition is carried out by local or central injection of the cells into the subject. In some other embodiments, the administration is via a systemic route such as peripheral administration. Additional guidance for preparation and administration of the pharmaceutical compositions of the invention are described in the art. See, e.g., Goodman & Oilman's The Pharmacological Bases of Therapeutics, Hardman et al., eds., McGraw-Hill Professional (10th ed., 2001); Remington: The Science and Practice of Pharmacy, Gennaro, ed., Lippincott Williams & Wilkins (20th ed., 2003); and
Pharmaceutical Dosage Forms and Drug Delivery Systems, Ansel et al. (eds.), Lippincott Williams & Wilkins (7th ed., 1999).
VI. TpoR agonist antibodies
[0073] The invention further provides TpoR agonist antibodies that can be employed in the methods of the invention. As described in the Examples, the inventor performed affinity maturation of the 3D9 antibody via yeast display, and obtained several variants that can also induce NK formation from AML cells. Accordingly, the invention provides antibodies or antigen-binding molecules that specifically bind to TpoR with the same binding specificity as that of the 3D9 variants (SEQ ID Nos:9-13). The TpoR agonist antibodies of the invention are preferably monoclonal antibodies like the antibodies exemplified in the Examples below. Preferably, they have the same binding specificities as that of the exemplified functional antibodies shown in Table 1. These antibodies typically harbor variable region sequences that are the same or substantially identical to that of the exemplified antibodies. General methods for preparation of monoclonal or polyclonal antibodies are well known in the art. See, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1998; Kohler & Milstein, Nature 256:495-497, 1975; Kozbor et al., Immunology Today 4:72, 1983; and Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy, 1985.
[0074] Some of the anti-TpoR agonist antibodies of the invention are derived from the 3D9-4 scFv variant antibody. This scFv antibody has an amino acid sequence shown in SEQ ID NO: 12. The sequences of the heavy chain and the light chain portions of the scFv are respectively shown in SEQ ID N0s: 14 and 15. The CDR sequences of the heavy chain variable region of this antibody are RDTFNTYG (HCDR1 ; SEQ ID NO:4), IIPIFGTA (HCDR2; SEQ ID NO:5), and CARDRRSGGSDYW (HCDR3; SEQ ID NO:21). The CDR sequences of its light chain variable region are QGLGRW (LCDR1 ; SEQ ID NO:7), AAS (LCDR2; SEQ ID NO:25), and QQTRRRPWT (LCDR3; SEQ ID NO:22). Some other TpoR agonist antibodies of the invention are derived from the 3D9-1, 3D9-2, 3D9-3, and 3D9-5 variants shown in Table 1. Heavy chain and light chain CDR sequences of these variants are shown in Table 2.
[0075] A typical intact antibody interacts with target antigen predominantly through amino acid residues that are located in the six heavy and light chain complementarity determining regions (CDR's). The TpoR agonist antibodies of the invention encompass antibodies or antigen-binding fragments having at least one of their heavy chain CDR sequences and light
chain CDR sequences that is the same as or substantially identical to the corresponding CDR sequence of the 3D9 antibody or its variant exemplified herein (e.g., antibody 3D9-4). Some of the agonist antibodies of the invention have the same binding specificity as that of the exemplified antibodies shown in Table 1. These antibodies can compete with the exemplified antibodies for binding to the TpoR receptor. The antibodies can additionally possess the same or similar functional properties as that of the exemplified antibodies, e.g., activating TpoR signaling pathway and/or induce NK cells from AML cells. Some agonist antibodies of the invention are homodimers having all CDR sequences in their variable regions of the heavy chain and light chain respectively identical to the corresponding CDR sequences of the exemplified TpoR agonist antibodies.
[0076] In addition to having CDR sequences respectively identical to the corresponding CDR sequences of an exemplified antibody (e.g., the 3D9-4 antibody), some of the TpoR agonist antibodies of the invention have their entire heavy chain and light chain variable region sequences respectively identical to the corresponding variable region sequences of the exemplified antibodies. In some other embodiments, other than the identical CDR sequences, the antibodies contain amino acid residues in the framework portions of the variable regions that are different from the corresponding amino acid residues of the exemplified antibodies. Relative to the exemplified antibodies, the agonist antibodies of the invention can undergo non-critical amino-acid substitutions, additions or deletions in the variable region without loss of binding specificity or effector functions, or intolerable reduction of binding affinity or receptor agonizing activities. Usually, antibodies incorporating such alterations exhibit substantial sequence identity to a reference antibody (e.g., the 3D9-4 variant antibody) from which they were derived. For example, the mature light chain variable regions of some of the agonist antibodies of the invention have at least 75% or at least 85% sequence identity to the sequence of the mature light chain variable region of the exemplified antibodies. Similarly, the mature heavy chain variable regions of the antibodies typically show at least 75% or at least 85% sequence identity to the sequence of the mature heavy chain variable region of the exemplified agonist antibodies. In various embodiments, the antibodies typically have their entire variable region sequences that are substantial identical (e.g., 75%, 85%, 90%, 95%, or 99%) to the corresponding variable region sequences of the exemplified antibodies. Some agonist antibodies of the invention
have the same specificity but improved affinity or receptor-agonizing activities if compared with the exemplified antibodies.
EXAMPLES
[0077] The following examples are provided to further illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims.
Example 1. AML cell differentiation induced by TpoR agonist antibody
[0078] Because signal transduction pathways, especially for cytokines, are degenerate, we tested whether our panel of agonist antibodies with their different mode of binding could induce stem cell-like acute myeloblasts leukemia (AML) cells to differentiate. We studied bone marrow or peripheral blood samples from 7 patients where the differentiation status of their AML according to the French-American-British (FAB) cooperative group was known. Six were classified as minimal maturation (Ml) and the other one was acute monocytic leukemia (M5). The one patient with M5 differentiated cells was treated for 4 months with Ara-C prior to collection of cells whereas the other 6 patients were untreated. Samples of leukemic cells were obtained by BM aspiration or from peripheral blood.
[0079] Initially, the leukemic cells from the bone marrow of an 83-year-old white female who had progressed from myelodysplasia syndrome to frank AML were studied in the greatest detail because they were the most stem cell like (Ml) (minimal maturation). A smear of the BM and FACS analysis showed that her BM was almost totally replaced by AML cells (greater than 93%) with a myeloid to erythroid ratio greater than 10: 1. The myeloid cells had round or slightly indented nuclei and were of normal female karyotype (Figs. la-c). According to FACS analysis, the CD34+/CD13+/CD33+ population of cells represented 2.4% of the BM whereas the CD34+/CD38" cell population represented 2.02 % of the BM. Based on the morphology and the cell surface phenotype, the leukemic cells were classified as Ml subtype.
[0080] The effect of two of the antibodies on this sentinel patient's AML cells was the most interesting. The agonist antibody to the granulocyte colony stimulating factor receptor (GCSFR) induced the AML cells to adopt a neural cell phenotype and express neural markers, as seen previously by us for normal CD34+ cells using this antibody. By contrast,
in these same cells, an agonist antibody that is highly specific for the thrombopoietin receptor (TPOR) induced a dendritic cell-like phenotype that was accompanied by expression of the dendritic cell marker CD1 lc (Figure 1). Differentiation begins on day two and appears to be complete by day four at which time about 80% of the cells were converted. This 3D9 TpoR agonist antibody was also able to induce formation of similar cells from bone marrow and peripheral blood from five out of seven other AML patients including the one classified as M5. By contrast natural TPO did not induce a dendritic like phenotype in AML cells (Figure 5C). Similar effects were observed for five out of seven other AML patients when their bone marrow or peripheral blood was studied, indicating that the NK induction can be generalizable to a majority of AML patients.
[0081] Importantly, this antibody agonist to the TPO receptor gave a totally different phenotype when normal CD34+ bone marrow cells instead of leukemic cells were studied. Here, like natural TPO, the antibody induced large numbers of megakaryocytes that is in keeping with the expected lineage conversion after activating the TpoR. No megakaryocytes were seen when either peripheral or bone marrow-derived AML cells were treated with the TpoR agonist antibody, indicative of the fact that the nature of the phenotype induced by antibody agonists may be cell context dependent.
[0082] In the course of the many experiments we carried out, we noticed that the induced cells could have an "early" or "late" phenotype" depending on the time in culture and somewhat on whether the culture dishes were collagen coated. When grown for short periods of time on collagen coated dishes, the induced cells are rounded and have extensive "needle like" projections and make large amounts of perforin, interferon gamma, and granzyme B (Figure 2, Figure 5). However, when grown for longer periods on glass surfaces, the induced cells have a more dendritic like phenotype (Fig. 1). Some of the projections from the induced cells appear to interact with the target cells that begin to bleb at their surface (Fig. IB). Given that the induced leukemic cells with an "early" phenotype make large amounts of molecules know to be associated with killer cells, we refer to them simply as NK cells. We further examined whether the NK cells with dendritic like phenotypes also produce molecules associated with killing. Like the more rounded cells, we found that these cells also produced large amounts of perforin, interferon y, and granzyme B (Fig.3, and Fig. 7). All these data indicate that the TpoR agonist antibody 3D9 can convert the AML cells into NK cells.
Example 2. Tumor cell killing
[0083] Based on serial qualitative observations at the level of light microscopy, the induced cells appeared to insert cytoplasmic ex- tensions into the neighboring, noninduced AML cells and kill them (Figure 4). To gain further information about the mechanism of killing, we studied the process by scanning electron microscopy, real time imaging, and quantitated the killing process. Multiple fine filopodia from the dendritic extensions of the killer cells attach to the target cells. Some of these filopodia actually appear to enter the interior of the target cell through very obvious holes that presumably are generated at the site of attachment by molecules in these filopodia such as perforin. Presumably perforin itself, granzyme B, and IFN- γ now access the cytoplasm of the target cells via the cytoplasmic extensions of the killer cells that have penetrated into the target cell interior. As observed by electron microscopy, the target cells now contain canyon-like fractures at their surface. These images support a killing mechanism similar to that studied in detail for NK cells (Cheng et al., Cell Mol. Immunol. 10:230-252, 2013).
[0084] We quantitated the killing potential of the AML cells that were induced by the antibody into NK cells. To do so, we used a FACS- based cytotoxicity assay in which target cells in suspension that were fluorescently labeled with calcein-AM were cocultured with antibody-induced NK cells that were attached to the dish. The calcein-AM-labeled target AML cells were incubated with NK cells or control cultures for 24 h. Propidium iodide (PI) was used to identify the dead cells. Thus, cells that both stain for calcein- AM and are PI+ represent dead target cells. The FACS analysis showed that the induced NK cells specifically killed 13-16% the target cells per 24 h (Fig. 9). This degree of killing occurs even though the required format for these experiments afforded less than the optimal potential for cell- cell interaction between attached killer cells and target cells in suspension. As a test of specificity, we studied whether the induced NK cells would kill breast cancer cells. The breast cancer cell line MDA-MB-231 was cocultured with induced NK cells or
undifferentiated AML cells as described above. Unlike the killing seen when AML cells are the targets, the induced NK cells did not specifically kill breast cancer cells, indicating that the requirement for killing goes beyond simple oncogenic transformation and may include a like-like recognition component.
Example 3. Different signal transduction activation kinetics
[0085] We analyzed the signal transduction pattern in AML cells after treatment with several doses of agonist antibody. In a previous study, we showed that the antibody induces rapid and strong STAT-3, AKT and ERK phosphorylation in normal CD34+ hematopoietic stem cells. Similarly, in AML cells the antibody induces efficient STAT-3, AKT and ERK phosphorylation. We tested the activation of phosphorylation at several time points using either the antibody or TPO. Both the antibody and TPO activated the phosphorylation of STAT-3 and ERK with similar kinetics but AKT was different. While the antibody increased the phosphorylation of AKT gradually, TPO showed different kinetics in that the activation of AKT phosphorylation was immediate and bi-phasic. To determine which signaling pathway(s) is necessary for NK cell differentiation by antibody, AML cells were co-treated with antibody and specific inhibitors of each signal pathway individually. Interestingly, antibody-induced NK cell differentiation was significantly blocked by the inhibitors of STAT-3 or PI 3-kinase that are upstream of AKT. However, the inhibitor of MEK that is upstream of ERK did not affect the differentiation of AML cells. These observations suggest that two of the three main signaling pathways of the TPOR (STAT-3 and PI 3-kinase) are required for antibody induction of NK cell differentiation from AML cells.
Example 4. Quantitative gene expression analysis
[0086] To gain more quantitative information about the gene expression that accompanies the differentiation of AML cells into NK cells and to further characterize the nature of the induced cells, whole transcriptome shotgun sequencing (RNAseq) was carried out. Untreated cells were compared to those treated with either TPO or agonist antibody. The overall gene expression profile of the groups treated with either the antibody or TPO were very different. The number of differently expressed transcripts was 3506 between the untreated and antibody treated cells versus 1902 between the untreated and TPO treated cells with a false discovery rate < 0.1 and average log2 (count per million) > 4 (Dataset S I). The whole transcriptome gene set enrichment analysis (GSEA) and ingenuity pathway analysis (IP A) showed that there were large increases in gene expression for molecules that encode genes associated with both developing and mature NK cells including those associated with signal transduction. These changes include large increases in the DC markers such as CD80, CD83, CD86, CD 123 and CCR7 and many NK markers of death receptor pathway such as
FAS, FAS ligand and TNFoc.
[0087] The consequences of having both dendritic and NK cell markers is interesting in that the IPA analysis showed that there is extensive "cross talk" between dendritic cells and NK cells in the gene set induced by our antibody. Moreover, after antibody treatment but not in control experiments, both the GSEA and IPA revealed up-regulation of molecules associated with cytotoxicity such as perforin and granzyme B, the interferon γ response, inflammation, and death receptor and TPOR signaling. Interestingly, many genes related to oxidative phosphorylation in mitochondria were also up regulated in the antibody-treated cells when compared to untreated cells. Probably, the killer cells have been reprogrammed to generate the large amounts of energy needed to synthesize killing molecules and deliver them. For instance, in going from AML to NK cells there is massive remodeling of the plasma membrane. In toto, the RNAseq analysis confirmed and added to the data obtained by morphological and immunocytochemical analysis.
Example 5. IPA Analysis of the mechanistic network
[0088] Aside from understanding the initiating events and identification of effector molecules, we were interested in the mechanism of the antibody-induced conversion of AML cells to NK cells. This conversion doubtless involves differential activation of signal transduction pathways (see above). To predict a mechanistic network, we have utilized the Upstream Analysis feature in Ingenuity Pathway Analysis (IPA) software. Upstream Analysis is based on prior knowledge of expected effects between transcriptional regulators and their target genes collected in the Ingenuity® Knowledge Base. This database includes Expression, Transcription and Protein-DNA binding relationships. Activation Z-score and Overlap p-value are two statistical measures to identify and rank significant regulators. The list of differentially expressed genes between the untreated and antibody treated cells with a false discovery rate < 0.1 and average log2 (count per million) > 4 was analyzed in IPA (-3500 DE genes). Interestingly, the Upstream Analysis ranked STAT1 among top five upstream transcription regulators based on activation Z-score and STAT3 was ranked 3rd based on Overlap p-value. In fact, there are 98 targets of ST ATI (overlap p-value<8.58E-20) and 153 targets of STAT3 (overlap p-value<2.02E-24) in the list of differentially expressed genes. The mechanistic network derived from the STAT1 analysis includes upstream regulators such as STAT3, RELA, IFNG, IL1B, IRF1 , IRF8, IRF9, JUN, MYC, NFKB 1 ,
NFKBIA, and SPIl which are predicted to be activated/inhibited based on a computationally generated directional network. However, this analysis doesn't require all the upstream regulators to be significantly changed. The mechanistic network derived from the STAT3 analysis, which shares many genes with STAT1 network, includes upstream regulators such as STAT1, RELA, IFNG, IL1B, IRF1 , IRF7, JU , NFKB 1 , NFKBIA, IL6, TNF, NR3C1, and Interferon alpha.
[0089] From a mechanistic point of view, the presence of STAT1 and STAT3 will allow formation of the heterodimer that binds to the interferon-gamma-activated sequence promoter element. Interestingly, we were also able to identify the V$STAT transcription factor binding site family as the second highest over-represented binding site family in the promoter regions of the top 500 up-regulated genes in the antibody-treated cells using Genomatix software (http://www.genomatix.de/").
Example 6. Additional studies on NK cells generated from AML cells.
[0090] Further experiments were performed to study NK cell differentiation from AML cells and their activities. First, a critical problem related to AML therapy is a high probability of recurrence of AML after chemotherapy. To examine if the 3D9 TpoR antibody also induces NK cells from relapsed AML cells (like newly diagnosed AML cells), relapsed AML cells were incubated with the antibody. NK cells markers including Perforin, Granzyme B and Interferon γ were then analyzed by confocal microscopy. The results are shown in Figure 10. As indicated in the figure, the antibody potently increased the differentiation of relapsed AML cells as well.
[0091] The killing process by the antibody-induiced NK cells was examined with confocal microscopy. As shown in Figure 1 1, it was found that the antibody-induced NK cells captured target AML cells using the tip of dendrites. An additional test was performed to determine if the TpoR antibody affects the TPO receptor signaling. It was observed that, like the Tpo ligand, the antibody activated the phosphorylation of Akt and Erk over various range of concentrations and time periods (Figure 12). Further, cytotoxic activities of NK cells induced from both newly diagnosed AML cells and relapsed AML cells by the TpoR antibody were demonstrated in vitro with undifferentiated AML cells (Figure 13). As shown in the figure, cytotoxic activity induced by the 3D9 antibody from relapsed AML cells is stronger than that induced from newly diagnosed AML cells.
[0092] Finally, we performed affinity maturation of the 3D9 antibody using yeast display and found 5 variants antibodies. Sequences of these 3D9 variants are shown in Tables 1 and 2. These 5 variants were tested for activity in induce MK differentiation from relapsed AML cells. Compared to the activity of 3D9, the variant antibodies showed varying activities in converting AML cells into NK cells (Figure 14). In particular, variant 4 showed higher potency than 3D9 in inducing differentiation of relapsed AML cells.
Example 7. Materials and methods
[0093] This example describes some of the material and methods that were employed in the exemplified embodiments herein.
[0094] Expression and purification of antibodies. The expression vector containing the antibody gene was transfected into 293F cells. Antibodies from the pooled supernatants were purified using HiTrap Protein G HP columns with AKTAxpress purifier. The buffer was exchanged to Dulbecco's PBS (pH 7.4) and the purified antibodies were stored at 4°C.
[0095] Culture of AML cells. Human AML BM and PB cells were isolated from patients and frozen at -80°C (AllCells). AML cells were cultured in StemSpan serum-free media (SFEM) from Stemcell technologies supplemented with streptomycin and penicillin.
[0096] Immunocytochemistry. Cells were fixed with 4% paraformaldehyde at room temperature (RT) for 15 min, blocked and stained with specific antibodies, followed by fluorophore conjugated secondary antibody staining. Hoechst 3342 (Cell signaling) and rhodamine-phalloidin (Life technologies). Incubation with all antibodies was carried out for 30 min at RT. After washing 3 times for 5 min, images were collected using a confocal microscope.
[0097] Flow cytometry. After co-culture, killer cells and Calcein-AM labeled target cells were stained with PI (Life technologies) to identify dead cells and washed with PBS. For quantification, Stained cells were sorted with a LSRII flow cytometer (Becton Dickinson).
[0098] Western blotting. To prepare total cell lysates, AML BM cells were washed with PBS and then lysed in lysis buffer (50 mM HEPES, pH 7.2, 150 mM NaCl, 50 mM NaF, 1 mM Na3V04, 10% glycerol, 1% Triton X-100). The lysates were then centrifuged at 15,000 rpm for 15 min at 4°C to remove aggregates, and the soluble proteins were denatured in Laemmli sample buffer (5 min at 95°C) and then separated by SDS-PAGE. The proteins were transferred to nitrocellulose membranes using the iBlot blotting system from Invitrogen
and blocked in PBST containing 5% BSA for 1 hr before being incubated with antibodies overnight at 4°C. After washing the membranes several times with PBST, the blots were incubated with horseradish peroxidase-conjugated anti-human or anti-rabbit antibody for 1 hr. The membranes were then washed with PBST and developed by ECL. The anti-STAT-3, anti-p-STAT-3 (Tyr-705), anti-AKT, anti-p-AKT (Thr-308), anti-ERKl/2 and anti-p- ERK1/2 (Thr-202/Tyr-204) antibodies were purchased from Cell signaling.
[0099] Electron microscopy. The cells were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer and a small volume was placed on a 13 mm Whatman PC filter. The cells were rinsed on the filter with PBS. The entire double filter was then clamped between nylon washers and the unit placed in 1% osmium tetroxide. After a PBS and water wash, the entire unit was dehydrated in an ethanol and placed in a critical point dryer. The nylon washers were then dismantled, the filters separated, and both filters mounted onto SEM stubs with carbon tape. The stubs with attached filters were then sputter coated with Iridium for subsequent examination and documentation on a Hitachi S-4800 SEM (Hitachi High Technologies).
[00100] PvNAseq and bioinformatic analysis. We prepared 3 replicas of R A from AML cells after treatment with PBS, antibody or TPO. RNAseq libraries were prepared with NuGEN Ovation RNA-Seq System V2. RNA was sequenced using an Illumina HISeq Analyzer 2000, Casava vl .8.2 genome analyzer pipeline, TopHat vl .4.1/Bowtie2 genome- alignment and Partek v6.6 mRNA annotation software. Statistical analyses were done with edgeR (Bioconductor), excluding genes with false discovery rates > 0.10, log2 (counts per million) > 4. GSEA was performed with gene set permutation, using gene sets from
MSigDB (www.broadinstiute.org/gsea/msigdb/index.jsp) or manually curated from excluding genes without HUGO approved symbols. We examined the molecular interactions to confirm the GSEA data that were captured previously. The differentially expressed genes were further analyzed using the IPA software (Ingenuity Systems, Redwood City, CA;
http://www.ingenuity.com). This all-in-one web-based software that makes use of the ingenuity pathways knowledge base (IPKB) to generate interaction networks of focus genes based on manually curated information reported in the literature.
[00101] Statistical analysis. The data are expressed as the means ± S.E. Statistical analysis was performed using the Student's t test or by one-way analysis of variance and the post hoc test, p- values of <0.05 were considered significant.
[00102] 3D9 TpoR agonist antibody amino acid sequence
[00103] scFv sequence (SEQ ID NO: 1)
[00104] MAQVQLVQSGAEVRKVGSSVKVSCKASRDTFNTYGISWVRQAPGQGLE
WMGGIIPIFGTADYAQKFRGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRKLG
GSDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQSPSSVSASVGDKVTITCRAS
QGLGRWLAWYQQEPGKAPKLLIYAASTLQRGVPSRFSGSGSGTDFTLTISSLQPEDF
ATYYCQQSNSFPWTFGQGTKLEIKR
[00105] Heavy chain variable region sequence (SEQ ID NO:2)
[00106] MAQVQLVQSGAEVRKVGSSVKVSCKASRDTFNTYGISWVRQAPGQGLE WMGGIIPIFGTADYAQKFRGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRKLG GSDYWGQGTLVTVSS
[00107] Light chain variable region sequence (SEQ ID NO:3)
[00108] DIVMTQSPSSVSASVGDKVTITCRASQGLGRWLAWYQQEPGKAPKLLIY AASTLQRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNSFPWTFGQGTKLEIK R
Table 1. Variants of 3D9 TpoR agonist antibody
Designa Sequence SEQ tion ID
NO:
3D9-1 MAQVQLVQSGAEVRKVGSSVKVSC ASRDTFNTYGISWVRQAPGQGLEWMGGIIP 9
IFGTADYAQ FRGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRRAGGSDYWGQGTL
VTVSSGGGGSGGGGSGGGGSDIVMTQSPSSVSASVGDKVTITCRASQGLGRWLAWYQQEP
GKAP LLIYAASTLQRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSRRNPWTFGQ
GTKLEIKRGLGGLEQKLISEEDL
3D9-2 AAQPAMAQVQLVQSGAEVRKVGSSVKVSCKASRDTFNTYGISWVRQAPGQGLEWMGGIIP 10
IFGTADYAQKFRGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRRAGGSDYWGQGTL
VTVSSGGGGSGGGGSGGGGSDIVMTQSPSSVSASVGDKVTITCRASQGLGRWLAWYQQEP
GKAPKLLIYAASTLQRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNNHNPWTFGQ
GTKLEIKRGLGGLEQKLISEEDL
3D9-3 AAQPAMAQVQLVQSGAEVRKVGSSVKVSCKASRDTFNTYGISWVRQAPGQGLEWMGGIIP 1 1
IFGTADYAQKFRGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRALGGSDYWGQGTL
VTVSSGGGGSGGGGSGGGGSDIVMTQSPSSVSASVGDKVTITCRASQGLGRWLAWYQQEP
GKAPKLLIYAASTLQRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAMHRPWTFGQ
GTKLEIKRGLGGLEQKLISEEDL
3D9-4 AAQPAMAQVQLVQSGAEVRKVGSSVKVSCKASRDTFNTYGISWVRQAPGQGLEWMGGIIP 12
IFGTADYAQKFRGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRRSGGSDYWGQGTL
VTVSSGGGGSGGGGSGGGGSDIVMTQSPSSVSASVGDKVTITCRASQGLGRWLAWYQQEP
GKAPKLLIYAASTLQRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTRRRPWTFGQ
GTKLEIKRGLGGLEQKLISEEDL
3D9-5 AAQPAMAQVQLVQSGAEVRKVGSSVKVSCKASRDTFNTYGISWVRQAPGQGLEWMGGIIP 13 IFGTADYAQKFRGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRRTGGSDYWGQGTL VTVSSGGGGSGGGGSGGGGSEIVLTQSPSSVSASVGDKVTITCRASQGLGRWLAWYQQEP GKAPKLLIYAASTLQRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTKWPPWTFGQ
GTKLEIKRGLGGLEQKLISEEDL
[00109] 3D9-4 variant antibody heavy chain variable region sequence (SEQ ID NO: 14)
[00110] MAQVQLVQSGAEVRKVGSSVKVSCKASPvDTFNTYGISWVRQAPGQGLE WMGGIIPIFGTADYAQKFRGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRRSG GSDYWGQGTLVTVSS
[00111] 3D9-4 variant antibody light chain variable region sequence (SEQ ID NO: 15)
[00112] DIVMTQSPSSVSASVGDKVTITCRASQGLGRWLAWYQQEPGKAPKLLIY AASTLQRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTRRRPWTFGQGTKLEIK R
Table 2 CDR sequences of 3D9 and variant antibodies
[00113] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
[00114] All publications, databases, GenBank sequences, patents, and patent applications cited in this specification are herein incorporated by reference as if each was specifically and individually indicated to be incorporated by reference.
Claims
1. A method for inducing formation of natural killer (NK) cells from acute myeloid leukemia (AML) cells, comprising contacting a population of AML cells with a TpoR agonist antibody under conditions sufficient to convert the AML cells into NK cells, thereby inducing the AML cells into NK cells, wherein the TpoR agonist antibody has the same binding specificity as that of an antibody comprising heavy chain and light chain CDR sequences (HCDRl -3 and LCDRl -3) respectively shown in (1) SEQ ID NOs:4, 5, 21, 7, 25 and 22; (2) SEQ ID NOs:4-7, 25 and 8; (3) SEQ ID NOs:4, 5, 16, 7, 25 and 17; (4) SEQ ID NOs:4, 5, 16, 7, 25 and 18; (5) SEQ ID NOs:4, 5, 19, 7, 25 and 20; or (6) SEQ ID NOs:4, 5, 23, 7, 25 and 24.
2. The method of claim 1, wherein the AML cells are cells isolated from a bone marrow sample or a peripheral blood sample of a human AML patient.
3. The method of claim 1, wherein the AML cells are human CD34+ leukemia cells.
4. The method of claim 3, wherein the human CD34+ leukemia cells are CD34+/CD33+ leukemia cells or CD34+/CD38- leukemia cells.
5. The method of claim 1, wherein the TpoR agonist antibody comprises heavy chain and light chain CDR sequences (HCDRl -3 and LCDRl-3) that are substantially identical to (1) SEQ ID NOs:4, 5, 21, 7, 25 and 22, respectively; (2) SEQ ID NOs:4-7, 25 and 8, respectively; (3) SEQ ID NOs:4, 5, 16, 7, 25, and 17, respectively; (4) SEQ ID NOs:4,
5, 16, 7, 25 and 18, respectively; (5) SEQ ID NOs:4, 5, 19, 7, 25 and 20, respectively; or (6) SEQ ID NOs:4, 5, 23, 7, 25 and 24, respectively.
6. The method of claim 1, wherein the TpoR agonist antibody comprises heavy chain and light chain CDR sequences (HCDRl-3 and LCDRl-3) that are respectively identical to (1) SEQ ID NOs:4, 5, 21, 7, 25 and 22; (2) SEQ ID NOs:4-7, 25 and 8; (3) SEQ ID NOs:4, 5, 16, 7, 25 and 17; (4) SEQ ID NOs:4, 5, 16, 7, 25 and 18; (5) SEQ ID NOs:4, 5, 19, 7, 25 and 20; or (6) SEQ ID NOs:4, 5, 23, 7, 25 and 24.
7. The method of claim 1 , wherein the TpoR agonist antibody comprises heavy chain and light chain variable region sequences respectively shown in (1) SEQ ID NO: 14 and SEQ ID NO: 15; or (2) SEQ ID NO:2 and SEQ ID NO:3.
8. The method of claim 1, wherein the TpoR agonist antibody comprises a scFv antibody fragment shown in SEQ ID NO: 12 or SEQ ID NO: l .
9. The method of claim 1 , wherein the contacting occurs in vitro by culturing the population of AML cells in the presence of the TpoR agonist antibody.
10. The method of claim 9, wherein culturing is for about 4 to 20 days.
11. The method of claim 1, further comprising detecting at least one cellular marker expressed by NK cells.
12. The method of claim 1 1 , wherein the at least one cellular marker expressed by NK cells is CD1 lc and one additional marker selected from the group consisting of perforin, granzyme B and interferon γ.
13. The method of claim 1, wherein the contacting occurs in vivo in a subject afflicted with acute myeloid leukemia.
14. The method of claim 13, wherein the antibody is a bispecific antibody or is conjugated to an entity that specifically recognizes a surface antigen of AML cells.
15. The method of claim 1 , further comprising enriching NK cells from the population of cells after contacting with the antibody to generate a homogenous population of NK cells.
16. A population natural killer (NK) cells produced by the method of claim 1.
17. A method for treating acute myeloid leukemia (AML) in a subject, comprising administering to the subject a pharmaceutical composition comprising a therapeutic amount of a TpoR agonist antibody, thereby treating AML in the subject, wherein the TpoR agonist antibody has the same binding specificity as that of an antibody
comprising heavy chain and light chain CDR sequences (HCDRl-3 and LCDRl-3) respectively shown in (1) SEQ ID NOs:4, 5, 21 , 7, 25 and 22; (2) SEQ ID NOs:4-7, 25 and 8; (3) SEQ ID N0s:4, 5, 16, 7, 25 and 17; (4) SEQ ID N0s:4, 5, 16, 7, 25 and 18; (5) SEQ ID N0s:4, 5, 19, 7, 25 and 20; or (6) SEQ ID NOs:4, 5, 23, 7, 25 and 24.
18. The method of claim 17, wherein the subject is afflicted with
undifferentiated acute myeloblasts leukemia (MO), acute myeloblasts leukemia with minimal maturation (Ml), acute myeloblasts leukemia with maturation (M2), acute promyelocytic leukemia (APL) (M3), acute myelomonocytic leukemia (M4), acute myelomonocytic leukemia with eosinophilia (M4 eos), acute monocytic leukemia (M5), acute erythroid leukemia (M6), or acute megakaryoblastic leukemia (M7).
19. A method for treating a cancer or an infection in a subject, comprising administering to the subject a pharmaceutical composition comprising a therapeutic amount of a TpoR agonist antibody, thereby treating AML in the subject, wherein the TpoR agonist antibody has the same binding specificity as that of an antibody comprising heavy chain and light chain CDR sequences (HCDRl-3 and LCDRl -3) respectively shown in (1) SEQ ID NOs:4, 5, 21 , 7, 25 and 22; (2) SEQ ID NOs:4-7, 25 and 8; (3) SEQ ID NOs:4, 5, 16, 7, 25 and 17; (4) SEQ ID NOs:4, 5, 16, 7, 25 and 18; (5) SEQ ID NOs:4, 5, 19, 7, 25 and 20; or (6) SEQ ID NOs:4, 5, 23, 7, 25 and 24.
20. The method of claim 19, wherein the subject is afflicted with a solid tumor.
21. The method of claim 19, wherein the subject is afflicted with a viral infection.
22. A method for killing leukemia cells in a subject, comprising (a) isolating a population of leukemia cells from the subject, (b) treating the isolated cells with a TpoR agonist antibody under conditions sufficient to convert the AML cells into NK cells, and (c) reintroducing the treated cells into the subject, thereby killing leukemia or lymphoid tumor cells in the subject; wherein the TpoR agonist antibody has the same binding specificity as that of an antibody comprising heavy chain and light chain CDR sequences (HCDRl -3 and
LCDRl-3) respectively shown in (1) SEQ ID NOs:4, 5, 21, 7, 25 and 22; (2) SEQ ID NOs:4- 7, 25 and 8; (3) SEQ ID NOs:4, 5, 16, 7, 25 and 17; (4) SEQ ID NOs:4, 5, 16, 7, 25 and 18; (5) SEQ ID N0s:4, 5, 19, 7, 25 and 20; or (6) SEQ ID NOs:4, 5, 23, 7, 25 and 24.
23. The method of claim 22, wherein the subject is afflicted with acute myeloid leukemia (AML), and the isolated cells are AML cells.
24. The method of claim 22, wherein the isolated cell population comprises at least lxlO2, lxlO3, lxl O4, lxl O5, or lxl O6 leukemia cells.
25. The method of claim 22, further comprising enriching N cells from the isolated population of cells after being treated with the antibody to generate a homogenous population of NK cells.
26. The method of claim 22, further comprising detecting in the treated cells at least one cellular marker expressed by NK cells.
27. The method of claim 26, wherein the at least one cellular marker expressed by NK cells is CD1 lc and one additional marker selected from the group consisting of perforin, granzyme B and interferon γ.
28. An antibody or antigen-binding fragment thereof which has the same binding specificity as that of an antibody comprising heavy chain and light chain CDR sequences (HCDRl -3 and LCDRl -3) respectively shown in (1) SEQ ID NOs:4, 5, 21, 7, 25 and 22; (2) SEQ ID NOs:4, 5, 16, 7, 25 and 17; (3) SEQ ID NOs:4, 5, 16, 7, 25 and 18; (4) SEQ ID NOs:4, 5, 19, 7, 25 and 20; or (5) SEQ ID NOs:4, 5, 23, 7, 25 and 24.
29. The antibody or antigen-binding fragment thereof of claim 28, comprising heavy chain and light chain CDR sequences (HCDRl-3 and LCDRl-3) that are substantially identical to (1) SEQ ID NOs:4, 5, 21, 7, 25 and 22, respectively; (2) SEQ ID NOs:4, 5, 16, 7, 25, and 17, respectively; (3) SEQ ID NOs:4, 5, 16, 7, 25 and 18, respectively; (4) SEQ ID NOs:4, 5, 19, 7, 25 and 20, respectively; or (5) SEQ ID NOs:4, 5, 23, 7, 25 and 24, respectively.
30. The antibody or antigen-binding fragment thereof of claim 28, comprising heavy chain and light chain CDR sequences (HCDRl-3 and LCDRl-3) that are respectively identical to (1 ) SEQ ID NOs:4, 5, 21 , 7, 25 and 22; (2) SEQ ID NOs:4, 5, 16, 7, 25 and 17; (3) SEQ ID NOs:4, 5, 16, 7, 25 and 18; (4) SEQ ID NOs:4, 5, 19, 7, 25 and 20; or (5) SEQ ID NOs:4, 5, 23, 7, 25 and 24.
31. The antibody or antigen-binding fragment thereof of claim 28, comprising heavy chain and light chain variable region sequences respectively shown in SEQ ID NO: 14 and SEQ ID NO: 15.
32. The antibody or antigen-binding fragment thereof of claim 28, comprising a scFv antibody fragment shown in SEQ ID NO: 12.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562182386P | 2015-06-19 | 2015-06-19 | |
US62/182,386 | 2015-06-19 | ||
US201562243314P | 2015-10-19 | 2015-10-19 | |
US62/243,314 | 2015-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016205784A1 true WO2016205784A1 (en) | 2016-12-22 |
Family
ID=57546405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/038338 WO2016205784A1 (en) | 2015-06-19 | 2016-06-20 | Methods and compositions for producing activated natural killer cells and related uses |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016205784A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018222901A1 (en) * | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
KR20220071892A (en) * | 2020-11-24 | 2022-05-31 | 재단법인대구경북과학기술원 | Novel anti-C-MPL antibodies and uses thereof |
WO2022114603A1 (en) * | 2020-11-24 | 2022-06-02 | 재단법인대구경북과학기술원 | Novel anti-c-mpl antibody and use thereof |
US11453862B2 (en) | 2019-07-08 | 2022-09-27 | Immunitybio, Inc. | Mononuclear cell derived NK cells |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100040600A1 (en) * | 2006-06-14 | 2010-02-18 | Chugai Seiyaku Kabushiki Kaisha | Agents for Promoting the Growth of Hematopoietic Stem Cells |
US20100081796A1 (en) * | 2008-09-26 | 2010-04-01 | Ulrich Brinkmann | Bispecific anti-egfr/anti-igf-1r antibodies |
US20100298398A1 (en) * | 2007-10-09 | 2010-11-25 | Alan Gewirtz | Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells |
WO2014035693A2 (en) * | 2012-08-31 | 2014-03-06 | The Scripps Research Institute | Methods and compositions related to modulators of eukaryotic cells |
-
2016
- 2016-06-20 WO PCT/US2016/038338 patent/WO2016205784A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100040600A1 (en) * | 2006-06-14 | 2010-02-18 | Chugai Seiyaku Kabushiki Kaisha | Agents for Promoting the Growth of Hematopoietic Stem Cells |
US20100298398A1 (en) * | 2007-10-09 | 2010-11-25 | Alan Gewirtz | Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells |
US20100081796A1 (en) * | 2008-09-26 | 2010-04-01 | Ulrich Brinkmann | Bispecific anti-egfr/anti-igf-1r antibodies |
WO2014035693A2 (en) * | 2012-08-31 | 2014-03-06 | The Scripps Research Institute | Methods and compositions related to modulators of eukaryotic cells |
Non-Patent Citations (2)
Title |
---|
[o] 17 September 2016 (2016-09-17), Database accession no. UniProtKB/TrEMBL * |
SEO ET AL.: "Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells.", MOL CANCER., vol. 6, no. 75, 2007, pages 1 - 8, XP055339158 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018222901A1 (en) * | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
JP2020522254A (en) * | 2017-05-31 | 2020-07-30 | エルスター セラピューティクス, インコーポレイテッド | Multispecific molecules that bind myeloproliferative leukemia (MPL) proteins and uses thereof |
US11453862B2 (en) | 2019-07-08 | 2022-09-27 | Immunitybio, Inc. | Mononuclear cell derived NK cells |
KR20220071892A (en) * | 2020-11-24 | 2022-05-31 | 재단법인대구경북과학기술원 | Novel anti-C-MPL antibodies and uses thereof |
WO2022114603A1 (en) * | 2020-11-24 | 2022-06-02 | 재단법인대구경북과학기술원 | Novel anti-c-mpl antibody and use thereof |
KR102579393B1 (en) | 2020-11-24 | 2023-09-18 | 재단법인대구경북과학기술원 | Novel anti-C-MPL antibodies and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6799895B2 (en) | Production method of TCRγδ + T cells | |
US5665557A (en) | Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof | |
KR101420344B1 (en) | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy | |
WO2012043651A1 (en) | Production method for myeloid blood cells | |
WO2016205784A1 (en) | Methods and compositions for producing activated natural killer cells and related uses | |
Sonoda | Human CD34-negative hematopoietic stem cells: The current understanding of their biological nature | |
Kellner et al. | Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL | |
Lee et al. | A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia | |
JPWO2020045368A1 (en) | Evaluation method for anti-infective drugs, vaccines, etc. using immortalized monocyte cells and inducible cells | |
Bloem et al. | Long‐term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMC‐dependent cell lines | |
Ikeda et al. | Transcriptional analysis of intravenous immunoglobulin resistance in Kawasaki disease using an induced pluripotent stem cell disease model | |
US20090117653A1 (en) | Method and apparatus for evaluating therapeutics on cancer stem cells | |
US20220403326A1 (en) | Media formulations and methods for producing progenitor t cells | |
WO2022204564A2 (en) | Methods and compositions for t-cell coculture potency assays and use with cell therapy products | |
WO2017048629A1 (en) | Antibodies for generating anti-inflammatory macrophage and related uses | |
WO2019023650A1 (en) | Compositions and methods for promoting hematopoietic stem cell regeneration | |
Lutz | Ly6D+ Siglec-H+ precursor cells contribute to conventional dendritic cells via a Siglec-H+ Zbtb46+ Ly6D+ intermediary stage | |
Funck | Innate immune cell crosstalk induces melanoma cell senescence | |
Dolinska | Understanding the role of bone marrow niche in myeloid malignancies | |
Beneforti | Role of Bone Marrow-Mesenchymal Stromal Cells and inflammation in the pre-leukemic phase of ETV6-RUNX1-positive childhood Acute Lymphoblastic Leukemia (ALL) | |
Zarin | The Role of Environmental Cues in γδ T-Cell Lineage Choice and Functional Programming | |
Twum | Interferon regulatory factor 8 (IRF8) transcriptionally regulates the macrophage response during tumor immunosurveillance | |
Belmonte | Understanding the role of extrinsic regulators in normal and malignant haematopoiesis | |
Thirlwell | Tissue origin dictates mesenchymal stromal cell chemokine and chemokine receptor repertoire and predicts in vitro chemotactic activity under homeostatic and inflammatory conditions | |
Kaur et al. | Microenvironment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16812608 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16812608 Country of ref document: EP Kind code of ref document: A1 |